# A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

> **NCT01896583** · PHASE2 · COMPLETED · sponsor: **Seldar Pharma, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Diarrhea Predominant Irritable Bowel Syndrome

## Interventions

- **DRUG:** ASP7147
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01896583
- **Lead sponsor:** Seldar Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-03
- **Final completion:** 2014-07
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896583, "A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01896583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*